ABT vs AIG Stock Comparison

Scores Breakdown

Metric	ABT	AIG
📈 Growth	18/30	12/30
💰 Profitability	17/20	14/20
🏦 Financial Health	18/20	12/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	4/10	7/10
Overall Score	71/100	53/100

Side-by-Side Summaries

ABT Analysis	AIG Analysis
📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.	📈 Growth & Financial Trajectory Across eight quarters from 2024Q4 to 2026Q2, Revenues rose from about $6.75B to $7.09B (~5% growth). Net income started strong at ~$1.334B in 2024Q4 but declined to ~$0.948B in 2026Q2, signaling earnings volatility. The trend features modest top-line expansion with a mix of quarterly profit swings; operating income in 2026Q2 was ~$1.264B on revenue of about $7.085B, implying positive leverage. Peak earnings occurred in late 2024 with a dip mid-2025, followed by partial recovery in 2026. 💰 Margins & Cash Flow Operating margin has hovered in the low-to-mid teens, with 2026Q2 delivering roughly an 18% margin. Net cash flow from operating activities was positive in most quarters, notably continuing cash flow of about $1.716B in 2026Q2, underscoring cash generation. Investing cash flow remained negative as the firm deployed assets, and financing cash flow was cash-using, tempering total free cash flow despite solid operating cash flow. 🛡️ Balance Sheet & Liquidity Assets run around $161–$165B; Liabilities around $122–$125B and Equity near $41B. The rough current ratio sits around 1.3–1.4, indicating liquidity cushion but sizable near-term obligations. Some quarters show atypical balance-sheet numbers (e.g., concentrated current liabilities), yet the overall base remains substantial for resilience. ⚠️ Key Drivers & Risks Drivers: Insurance premiums and investment income; rising interest-rate environment. Risks: Earnings volatility and sensitivity to reserve and regulatory changes; near-term liquidity and leverage considerations.

ABT Analysis

AIG Analysis

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

📈 Growth & Financial Trajectory

Across eight quarters from 2024Q4 to 2026Q2, Revenues rose from about $6.75B to $7.09B (~5% growth). Net income started strong at ~$1.334B in 2024Q4 but declined to ~$0.948B in 2026Q2, signaling earnings volatility. The trend features modest top-line expansion with a mix of quarterly profit swings; operating income in 2026Q2 was ~$1.264B on revenue of about $7.085B, implying positive leverage. Peak earnings occurred in late 2024 with a dip mid-2025, followed by partial recovery in 2026.

💰 Margins & Cash Flow

Operating margin has hovered in the low-to-mid teens, with 2026Q2 delivering roughly an 18% margin. Net cash flow from operating activities was positive in most quarters, notably continuing cash flow of about $1.716B in 2026Q2, underscoring cash generation. Investing cash flow remained negative as the firm deployed assets, and financing cash flow was cash-using, tempering total free cash flow despite solid operating cash flow.

🛡️ Balance Sheet & Liquidity

Assets run around $161–$165B; Liabilities around $122–$125B and Equity near $41B. The rough current ratio sits around 1.3–1.4, indicating liquidity cushion but sizable near-term obligations. Some quarters show atypical balance-sheet numbers (e.g., concentrated current liabilities), yet the overall base remains substantial for resilience.

⚠️ Key Drivers & Risks

Drivers: Insurance premiums and investment income; rising interest-rate environment.
Risks: Earnings volatility and sensitivity to reserve and regulatory changes; near-term liquidity and leverage considerations.

Similar Companies

ABBV Score: 64 BSX Score: 79 DXCM Score: 82 ELV Score: 62 ISRG Score: 84 JNJ Score: 86 MDT Score: 78 TMO Score: 75 TSLA Score: 64

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"